FrancophonIA/ELRC3.0 huggingface dataset:
English: • leptospirosis, a bacterial disease that may be transmitted via infected urine and result in bleeding,
Estonian: • leptospiroos - bakteriaalhaigus, mis kandub edasi nakatunud uriini kaudu ning põhjustab verejooksu, hepatiiti (maksapõletikku) ja ikterust või nefriiti (neerupõletikku).
English: Why has Versican Plus Pi/L4 been approved?
Estonian: Miks Versican Plus Pi/L4 heaks kiideti?
English: What is Versican Plus Pi/L4?
Estonian: Mis on Versican Plus Pi/L4?
English: Versican Plus Pi/L4 is available as a lyophilisate (freeze-dried pellet) with solvent for injection.
Estonian: Vaktsiini Versican Plus Pi/L4 turustatakse süstesuspensiooni lüofilisaadi (külmkuivatatud graanulid) ja lahustina.
English: What is the risk associated with Versican Plus Pi/L4?
Estonian: Mis riskid vaktsiiniga Versican Plus Pi/L4 kaasnevad?
English: Other information about Versican Plus Pi/L4:
Estonian: Muu teave vaktsiini Versican Plus Pi/L4 kohta
English: How has Versican Plus Pi/L4 been studied?
Estonian: Kuidas vaktsiini Versican Plus Pi/L4 uuriti?
English: How does Versican Plus Pi/L4 work?
Estonian: Kuidas Versican Plus Pi/L4 toimib?
English: What is Versican Plus Pi/L4 used for?
Estonian: Milleks vaktsiini Versican Plus Pi/L4 kasutatakse?
English: The recommended dose is one 150 microgram capsule, once a day at the same time each day.
Estonian: Soovitatav annus on üks 150 µg kapsel üks kord ööpäevas iga päev samal kellaajal.
English: The full EPAR for Onbrez Breezhaler can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst ravimi Onbrez Breezhaler kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: To receive a dose, the patient places a capsule into the inhaler and breathes the powder in through the mouth.
Estonian: Annuse manustamiseks asetab patsient kapsli inhalaatorisse ja hingab pulbrit sisse suu kaudu.
English: The medicine contains the active substance indacaterol.
Estonian: Ravim sisaldab toimeainena indakaterooli.
English: European Commission granted a marketing authorisation valid throughout the European Union for Onbrez Breezhaler on 30 November 2009.
Estonian: Euroopa Komisjon andis ravimi Onbrez Breezhaler müügiloa, mis kehtib kogu Euroopa Liidus, 30. novembril 2009.
English: The main measure of effectiveness was based on changes in the patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second) after 12 weeks.
Estonian: Efektiivsuse põhinäitaja aluseks oli patsientide forsseeritud ekspiratoorse mahu (FEV1, suurim õhukogus, mida inimene suudab 1 sekundi jooksul välja hingata) muutus 12 nädala järel.
English: It works by attaching to beta-2 receptors that are found in the muscle cells of many organs and that cause the muscles to relax.
Estonian: See seondub beeta-2-retseptoritega, mida leidub paljude elundite lihasrakkudes ja mis võimaldavad lihaste lõdvestumist.
English: The increase in FEV1 was 130 ml with tiotropium, and 80 ml with formoterol.
Estonian: Tiotroopiumiga suurenes FEV1 130 ml võrra ja formoterooliga 80 ml võrra.
English: This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.
Estonian: See lõõgastab hingamisteede lihased, hoides hingamisteed avatuna, nii et patsiendil on kergem hingata.
English: Overall, the effects of the 150 and 300 microgram doses of Onbrez Breezhaler were similar, but the results showed that the 300 microgram dose may provide better relief in patients with more severe disease.
Estonian: Ravimi Onbrez Breezhaler 150 ja 300 µg annuste toime oli üldiselt sarnane, kuid tulemused näitasid, et 300 µg annus võib rohkem leevendada raskema haigusega patsientide sümptomeid.
English: Therefore, the Agency decided that Onbrez Breezhaler's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Seetõttu otsustas ravimiamet, et ravimi Onbrez Breezhaler kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Other common side effects include chest pain, cough and muscle cramps.
Estonian: Muud sagedased kõrvalnähud on valu rinnus, köha ja lihaskrambid.
English: What measures are being taken to ensure the safe and effective use of Onbrez Breezhaler?
Estonian: Mis meetmed võetakse, et tagada ravimi Onbrez Breezhaler ohutu ja efektiivne kasutamine?
English: Onbrez Breezhaler capsules, which contain a power for inhalation, are only used with a Onbrez Breezhaler inhaler and must not be swallowed.
Estonian: Ravimi Onbrez Breezhaler kapsleid, mis sisaldavad inhalatsioonipulbrit, tohib kasutada üksnes ravimi Onbrez Breezhaler inhalaatoris ja neid ei tohi alla neelata.
English: In three main studies involving over 4,000 patients with COPD, Onbrez Breezhaler was compared with placebo (a dummy treatment), tiotropium or formoterol (other inhaled medicines used to treat COPD).
Estonian: Kolmes põhiuuringus, milles osales üle 4000 kroonilise obstruktiivse kopsuhaigusega patsiendi, võrreldi ravimit Onbrez Breezhaler platseebo (näiv ravim), tiotroopiumi ja formoterooliga (muud kroonilise obstruktiivse kopsuhaiguse raviks kasutatavad inhaleeritavad ravimid).
English: The Agency also noted that there were no major safety concerns with Onbrez Breezhaler, with side effects being manageable and similar to other beta-2 adrenergic receptor agonist medicines.
Estonian: Ravimiamet märkis samuti, et ravimiga Onbrez Breezhaler ei ole täheldatud suuri ohutusprobleeme, kusjuures selle kõrvalnähud on kontrolli all hoitavad ja sarnanevad teiste beeta-2-adrenergilise retseptori agonistide kõrvalnähtudega.
English: COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.
Estonian: Krooniline obstruktiivne kopsuhaigus on krooniline haigus, mille korral kopsude bronhid ja alveoolid on kahjustatud või blokeerunud ning see põhjustab hingamisraskusi.
English: The most common side effects with Onbrez Breezhaler (which may affect more than 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat) and upper respiratory tract infection (infection of the nose and throat).
Estonian: Ravimi Onbrez Breezhaler kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on nasofarüngiit (nina- ja kurgupõletik) ja ülemiste hingamisteede infektsioon.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Onbrez Breezhaler have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Onbrez Breezhaler ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Onbrez Breezhaler indacaterol
Estonian: Onbrez Breezhaler indakaterool
English: This is a summary of the European public assessment report (EPAR) for Onbrez Breezhaler.
Estonian: See on ravimi Onbrez Breezhaler Euroopa avaliku hindamisaruande kokkuvõte.
English: On average, the increase in FEV1 in patients who received Onbrez Breezhaler was between 150 to 190 ml, while for patients who received placebo the change in FEV1 ranged from a decrease of 10 ml to an increase of 20 ml.
Estonian: FEV1 suurenes keskmiselt 150-190 ml võrra ravimit Onbrez Breezhaler saanud patsientidel ja vähenes kuni 10 ml võrra või suurenes kuni 20 ml võrra platseebot saanud patsientidel.
English: Onbrez Breezhaler is used for maintenance (regular) treatment.
Estonian: Ravimit Onbrez Breezhaler kasutatakse säilitusraviks (tavaliseks raviks).
English: Onbrez Breezhaler is a medicine that is used to keep the airways open in adults with chronic obstructive pulmonary disease (COPD).
Estonian: Onbrez Breezhaler on ravim, mida kasutatakse hingamisteede avatuna hoidmiseks kroonilise obstruktiivse kopsuhaigusega täiskasvanutel.
English: The active substance in Onbrez Breezhaler, indacaterol, is a beta-2 adrenergic receptor agonist.
Estonian: Ravimi Onbrez Breezhaler toimeaine indakaterool on beeta-2-adrenergilise retseptori agonist.
English: What is Onbrez Breezhaler and what is it used for?
Estonian: Mis on Onbrez Breezhaler ja milleks seda kasutatakse?
English: For more information about treatment with Onbrez Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate ravimiga Onbrez Breezhaler toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For the full list of all side effects and restrictions with Onbrez Breezhaler, see the package leaflet.
Estonian: Ravimi Onbrez Breezhaler kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: For practical information about using Onbrez Breezhaler, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate ravimi Onbrez Breezhaler kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Other information about Onbrez Breezhaler
Estonian: Muu teave ravimi Onbrez Breezhaler kohta
English: Why is Onbrez Breezhaler approved?
Estonian: Miks Onbrez Breezhaler heaks kiideti?
English: The doctor may increase the dose to one 300 microgram capsule once a day in cases of severe COPD.
Estonian: Rasketel kroonilise obstruktiivse kopsuhaiguse juhtumitel võib arst annust suurendada ühe 300 µg kapslini üks kord ööpäevas.
English: It is not intended to provide practical advice on how to use Onbrez Breezhaler.
Estonian: Hindamisaruandes ei anta ravimi Onbrez Breezhaler kasutamise praktilisi nõuandeid.
English: The European Medicines Agency concluded that Onbrez Breezhaler was shown to be effective at improving the lung function in COPD.
Estonian: Euroopa Ravimiamet järeldas, et Onbrez Breezhaler on tõendite põhjal efektiivne kopsutalitluse parandamisel kroonilise obstruktiivse kopsuhaiguse korral.
English: When Onbrez Breezhaler is inhaled, indacaterol reaches the receptors in the airways and activates them.
Estonian: Ravimi Onbrez Breezhaler inhaleerimisel puutub indakaterool kokku hingamisteedes olevate retseptoritega ja aktiveerib need.
English: What are the risks associated with Onbrez Breezhaler?
Estonian: Mis riskid ravimiga Onbrez Breezhaler kaasnevad?
English: How does Onbrez Breezhaler work?
Estonian: Kuidas Onbrez Breezhaler toimib?
English: Onbrez Breezhaler was more effective than placebo at improving how well the lungs work in patients with COPD.
Estonian: Onbrez Breezhaler oli kroonilise obstruktiivse kopsuhaigusega patsientide kopsutalitluse parandamisel platseebost efektiivsem.
English: How is Onbrez Breezhaler used?
Estonian: Kuidas ravimit Onbrez Breezhaler kasutatakse?
English: What benefits of Onbrez Breezhaler have been shown in studies?
Estonian: Milles seisneb uuringute põhjal ravimi Onbrez Breezhaler kasulikkus?
English: 20 October 2015 EMA/481797/2015
Estonian: oktoober 2015 EMA/828108/2015
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom persist for more than one week.
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom20.
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in this way for at least 30 years (including at least 15 years within the EU).
Estonian: See tähendab, et kuigi puuduvad kliinilistest uuringutest saadud piisavad tõendid, on tõenäoline, et need taimsed ravimid on tõhusad, ja on tõendeid, et neid on sel viisil ohutult kasutatud vähemalt 30 aastat (sh vähemalt 15 aastat Euroopa Liidus).
English: The expressed juice may then be dried.
Estonian: Seejärel võib pressitud mahla kuivatada.
English: When used for prevention and treatment of common cold, cases of serious allergic reactions (such as Stevens-Johnson syndrome, asthma and anaphylactic shock) have been reported, especially in patients who are atopic (have a predisposition to allergic reactions).
Estonian: Külmetuse ennetamiseks ja raviks kasutamisel on teatatud raskete allergiliste reaktsioonide juhtudest (nt Stevensi-Johnsoni sündroom, astma ja anafülaktiline šokk), eriti atoopilistel (allergiliste reaktsioonide eelsoodumusega) patsientidel.
English: However, these data were insufficient to be used as evidence of effectiveness and the HMPC conclusions for this indication are based on the medicines' long-standing use.
Estonian: Nendest andmetest aga ei piisanud efektiivsuse tõendamiseks ja taimsete ravimite komitee järeldused selle näidustuse kohta tuginevad ravimite pikaajalisele kasutusele.
English: Purple coneflower herb medicines should only be used in adults and adolescents above the age of 12 years.
Estonian: Punase siilkübara ürti sisaldavaid ravimeid tohib kasutada üksnes täiskasvanutel ja üle 12-aastastel noorukitel.
English: For further information on the studies assessed by the HMPC, see the HMPC assessment report.
Estonian: Üksikasjalikku teavet taimsete ravimite komitee poolt hinnatud uuringute kohta vaata komitee hindamisaruandest.
English: Further information on the risks associated with purple coneflower herb medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave punase siilkübara ürti sisaldava ravimiga kaasnevate riskide, sh selle ohutu kasutamise ettevaatusabinõude kohta, on ravimtaime monograafias Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Further information on the HMPC assessment of purple coneflower herb medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Estonian: Lisateave punase siilkübara ürti sisaldava ravimi hinnangu kohta, sh komitee kokkuvõtte detailne kirjeldus, on Euroopa Ravimiameti veebilehe jaotises „All documents”: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Purple coneflower herb medicines must not be used in patients who are hypersensitive (allergic) to purple coneflower or other plants of the Asteraceae (Compositae) family.
Estonian: Punase siilkübara ürti sisaldavaid ravimeid ei tohi kasutada patsiendid, kes on ülitundlikud (allergilised) punase siilkübara või teiste Asteraceae (Compositae) sugukonna taimede vastu.
English: Any applications for the licensing of medicines containing purple coneflower herb have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Estonian: Punase siilkübara ürti sisaldava ravimi müügiloa taotlus tuleb esitada riiklikule ravimiametile, mis hindab taimse ravimi müügiloa taotlust, võttes arvesse taimsete ravimite komitee teaduslike järelduste kokkuvõtet.
English: The most relevant clinical trials performed in adults indicated that purple coneflower herb medicines containing the expressed juice to be taken by mouth can prevent and improve the symptoms of cold more rapidly than placebo when taken early.
Estonian: Kõige asjakohasemad läbiviidud kliinilised uuringud täiskasvanutel näitasid, et kui punase siilkübara ürdi pressitud mahla sisaldavaid suukaudseid ravimeid võetakse piisavalt vara, võivad need külmetuse sümptomeid ennetada ja leevendada kiiremini kui platseebo.
English: For the treatment of superficial wounds, a doctor or a qualified healthcare practitioner should be consulted if symptoms
Estonian: Pindmiste haavade ravis tuleb arsti või pädeva tervishoiutöötaja poole pöörduda juhul, kui sümptomid püsivad üle ühe nädala.
English: Herbal medicines containing purple coneflower herb preparations are usually available in liquid or solid forms to be taken by mouth and in semi-solid (such as ointments) or liquid forms to be applied to the skin.
Estonian: Punase siilkübara ürdi valmistisi sisaldavaid taimseid ravimeid turustatakse tavaliselt suukaudsete vedelate või tahkete ainetena ja nahale kantavate pooltahkete (nt salvid) või vedelate ainetena.
English: The flowering aerial parts for medicinal uses are obtained from plants that have been cultivated or found in the wild.
Estonian: Meditsiiniliselt kasutatavad maapealsed õitsvad osad saadakse kasvatatud või loodusest leitud taimedelt.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing purple coneflower herb.
Estonian: ELi liikmesriigid võtavad taimsete ravimite komitee järeldusi arvesse, kui nad hindavad punase siilkübara ürti sisaldavate taimsete ravimite müügilubade taotlusi.
English: Purple coneflower herb is the common name for the flowering aerial parts of the plant Echinacea purpurea (L.) Moench.
Estonian: Punase siilkübara ürt on taime Echinacea purpurea (L.) Moench maapealsete õitsvate osade üldnimetus.
English: In its assessment, the HMPC considered a number of clinical studies comparing purple coneflower herb medicines with placebo for short-term prevention and treatment of upper airways infections.
Estonian: Hindamise käigus vaatas taimsete ravimite komitee läbi mitu kliinilist uuringut, milles võrreldi punase siilkübara ürti sisaldavaid ravimeid platseeboga ülemiste hingamisteede infektsioonide lühiajalises ennetamises ja ravis.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of purple coneflower herb.
Estonian: See on taimsete ravimite komitee teaduslike järelduste kokkuvõte, mis käsitleb punase siilkübara ürdi meditsiinilisi kasutusviise.
English: The HMPC also concluded that, on the basis of their long-standing use, purple coneflower herb medicines to be applied to the skin can be used to treat small superficial wounds.
Estonian: Lisaks järeldas taimsete ravimite komitee, et pikaajalise kasutamise põhjal tohib punase siilkübara ürti sisaldavaid nahale kantavaid ravimeid kasutada väikeste pindmiste haavade raviks.
English: What are the risks associated with purple coneflower herb medicines?
Estonian: Mis riskid kaasnevad punase siilkübara ürti sisaldava ravimiga?
English: The HMPC conclusions on the use of purple coneflower herb medicines for superficial wounds are based on their ‘traditional use'.
Estonian: Taimsete ravimite komitee järeldused punase siilkübara ürti sisaldavate ravimite kasutamise kohta pindmiste haavade korral põhinevad nende traditsioonilisel kasutusel.
English: The HMPC conclusions on the short-term use of purple coneflower herb medicines to prevent and treat common cold are based on their ‘well-established use' in this indication.
Estonian: Taimsete ravimite komitee järeldused punase siilkübara ürti sisaldavate ravimite lühiajalise kasutamise kohta külmetuse ennetamiseks ja raviks põhinevad nende hästi tõestatud meditsiinilisel kasutamisel selle seisundi korral.
English: The HMPC noted possible beneficial effects on wound healing in animal studies.
Estonian: Taimsete ravimite komitee märkis, et loomuuringud on näidanud võimalikku kasulikku toimet haavade paranemisele.
English: For practical information about using purple coneflower herb medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
Estonian: Kui vajate punase siilkübara ürti sisaldava ravimi kasutamise kohta praktilisi nõuandeid, lugege ravimi pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: What evidence supports the use of purple coneflower herb medicines?
Estonian: Millised tõendid toetavad punase siilkübara ürti sisaldava ravimi kasutamist?
English: This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU.
Estonian: See tähendab, et nende ravimite kõnealusel näidustusel kasutamise efektiivsuse ja ohutuse kohta on Euroopa Liidus avaldatud teaduskirjandusandmeid vähemalt 10 aastat.
English: For more information about treatment with purple coneflower herb medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Estonian: Kui vajate lisateavet punase siilkübara ürti sisaldava ravimi kasutamise kohta, lugege palun pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Purple coneflower herb preparations are made by expressing the juice of the fresh herb.
Estonian: Punase siilkübara ürdi valmistisi tehakse värskest ürdist mahla pressides.
English: The HMPC concluded that purple coneflower herb medicines to be taken by mouth can be used short term for the prevention and treatment of common colds.
Estonian: Taimsete ravimite komitee järeldas, et punase siilkübara ürti sisaldavaid suukaudseid ravimeid tohib kasutada lühiajaliselt külmetuse ennetamiseks ja raviks.
English: Information on the use and licensing of purple coneflower leaf medicines in EU Member States should be obtained from the relevant national authorities.
Estonian: ELi liikmesriikides saab teavet punase siilkübara ürti sisaldava ravimi kasutamise ja müügiloa kohta riiklikult ravimiametilt.
English: This summary is not intended to provide practical advice on how to use medicines containing purple coneflower herb.
Estonian: Kokkuvõttes ei anta punase siilkübara ürti sisaldava ravimi kasutamise kohta praktilisi nõuandeid.
English: What is purple coneflower herb?
Estonian: Mis on punase siilkübara ürt?
English: How are purple coneflower herb medicines approved in the EU?
Estonian: Kuidas antakse Euroopa Liidus punase siilkübara ürti sisaldavale ravimile müügiluba?
English: Detailed instructions on how to take purple coneflower herb medicines and who can use them can be found in the package leaflets that come with the medicines.
Estonian: Punase siilkübara ürti sisaldavate ravimite võtmise ja näidustuse üksikasjalik teave on ravimi pakendi infolehel.
English: Other information about purple coneflower herb medicines
Estonian: Muu teave punase siilkübara ürti sisaldava ravimi kohta
English: A doctor or pharmacist should be consulted if symptoms persist for more than 10 days when using purple coneflower herb medicines for the treatment of common colds.
Estonian: Kui punase siilkübara ürti sisaldavaid ravimeid kasutatakse külmetuse ravis ja sümptomid püsivad kauem kui 10 päeva, tuleb pöörduda arsti või apteekri poole.
English: Allergic reactions such as rash have been reported with the use of purple coneflower herb medicines.
Estonian: Punase siilkübara ürti sisaldavate ravimite kasutamisel on teatatud allergilistest reaktsioonidest, nagu lööve.
English: Convincing data to identify a patient population in which the benefits of buflomedil clearly outweigh its identified risks.
Estonian: veenvad andmed patsientide populatsiooni kohta, kellel buflomediilist saadav kasu kaaluks selgelt üles kindlaks tehtud riskid.
English: For the suspension to be lifted the Marketing Authorisation Holders would need to provide the National Competent Authorities with the following:
Estonian: Müügilubade peatamise otsuse tühistamiseks peavad müügiloa hoidjad esitama riiklikele pädevatele asutustele järgmised andmed:
English: Annex III Conditions for lifting the suspension
Estonian: Lisa III Müügilubade peatamise otsuse tühistamise tingimused
English: The tablets contain 100, 200, 400, 600 or 800 micrograms of fentanyl.
Estonian: Tabletid sisaldavad 100, 200, 400, 600 või 800 µg fentanüüli.
English: Each patient ranked their pain intensity on an 11-point scale.
Estonian: Iga patsient hindas valu intensiivsust 11-punktisel skaalal.
English: It is a well-known substance, which has been used to control pain for many years.
Estonian: See on tuntud aine, mida on kasutatud palju aastaid valu kontrolli all hoidmiseks.